Navigation Links
Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease

NEW YORK, March 27 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug delivery for Parkinson's disease.

The funding was awarded under the Foundation's Improving Delivery of Parkinson's Disease Therapeutics to the Brain. The program is designed to address two major challenges to the development of transformative treatments for Parkinson's disease: the need for non-invasive drug delivery technologies allowing therapeutics to cross the blood-brain barrier, and the need to more precisely understand how molecules move inside the central nervous system in order to target treatments to specific regions of the brain.

Funded projects are listed below. Full information on funded projects, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

Image-guided Gene Delivery for Parkinson's

Krysztof Bankiewicz, M.D., Ph.D., University of California, San Francisco

Convection Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Human Parkinson's Disease

Jeff Elias, M.D., University of Virginia, and Russell Lonser, M.D., National Institute of Neurodegenerative Disease and Stroke

Real-time Monitoring of Targeting, Delivery, and Spread of Therapeutic Agents in the Brain

Samir Jafri, Ph.D., University of Maryland, Baltimore, and Cha-Min Tang, M.D., Ph.D., University of Maryland School of Medicine

Utilizing Novel Tracers to Determine the Distribution of Therapeutic Agents In Vivo

RamakrishnaVenugopalan, Ph.D., Codman and Shurtleff, Inc.

Deep Brain Imaging to Determine the Movement of Compounds Relevant to Parkinson's Disease

Mark Saltzman, Ph.D., and Michael Levene, Ph.D., Yale University

Novel Antibodies for the Delivery of Parkinson's Therapeutics

Eric Shusta, Ph.D., and Clive Svendson, Ph.D., University of Wisconsin, Madison

Intranasal Gene Therapy: Next Steps

Barbara Lee Waszczak, Ph.D., Northeastern University

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.

SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
Breaking Medicine News(10 mins):